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Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile.
Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and
in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the pharmacokinetics and metabolism of
fulvestrant, which support the rationale for drug delivery as a single, once-monthly intramuscular injection, and show that this agent
has minimal potential to be the subject, or cause, of significant cytochrome p450-mediated drug interactions.
British Journal of Cancer (2004) 90(Suppl 1), S7–S10. doi:10.1038/sj.bjc.6601630 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: fulvestrant; ‘Faslodex’; oestrogen receptor; pharmacokinetics; metabolism
                            
Fulvestrant (‘Faslodex’) is an oestrogen receptor (ER) antagonist
with no agonist effects and a novel pharmacological profile,
downregulating cellular levels of both the ER and progesterone
receptor (PgR) (Howell et al, 2000; Robertson et al, 2001).
Fulvestrant competes with oestrogen for binding to the ER. In
order to achieve effective inhibition of oestrogen-controlled
proliferation, downregulation of the ER must be sustained over
time. Therefore, in contrast to some other antitumour agents (such
as cytotoxic chemotherapies, which are administered in cyclic
regimens) sustained exposure to fulvestrant via chronic adminis-
tration is required for activity. Oral delivery was explored in
animals and man using a range of formulations; however, the low
level of bioavailability and presystemic metabolism meant that this
was not an appropriate route of administration (Harrison et al,
2003). Therefore, a long-acting, intramuscular (i.m.) formulation
of fulvestrant was developed that gives adequate bioavailability
and allows controlled release of the drug. This paper will review
fulvestrant pharmacokinetic and metabolism data that have been
obtained from preclinical studies and from trials in healthy
volunteers and in postmenopausal women with breast cancer.
PHARMACOKINETICS OF FULVESTRANT
Single-dose intravenous studies
An intravenous (i.v.) formulation of fulvestrant was developed for
use in pharmacokinetic investigations since plasma concentrations
of fulvestrant administered by the i.m. route are determined by the
rate of release of the drug from the injection site and, therefore, do
not accurately reflect the elimination kinetics of the compound. A
short-acting i.m. formulation was used to mimic steady-state
plasma concentrations obtained using long-acting fulvestrant, and
to overcome the difficulties of obtaining pharmacokinetic data
with the long-acting formulation.
The pharmacokinetics of a number of doses of i.v. fulvestrant
have been determined in healthy men and postmenopausal
women. Following i.v. administration, fulvestrant plasma concen-
trations increased rapidly, reaching an approximate steady state by
the end of the 1-h infusion. Plasma concentrations declined in a
triexponential manner, falling very rapidly with an approximate
five-fold reduction within 30min (Harrison et al, 2003). Over
several single-dose i.v. studies, the terminal elimination half-life
(t1/2) of i.v. fulvestrant ranged from 13.5 to 18.5h. Fulvestrant was
subject to extensive and rapid distribution, with estimates of the
volume of distribution (Vss) at the steady state ranging from 3.0 to
5.3lkg
 1. Clearance of the compound from the plasma was high,
with mean values between 9.3 and 14.3mlminkg
 1, which is
similar to hepatic plasma flow (nominally 10.5mlminkg
 1), and
suggests that the compound is cleared by the liver and possibly by
extrahepatic metabolism. Pharmacokinetic modelling showed that
the plasma concentration data fitted a three-compartment infusion
model (Harrison et al, 2003).
Single-dose i.m. studies using the short- and long-acting
fulvestrant formulations
Single-dose pharmacokinetic studies using various doses (2, 6, 18
and 36mg) of the short-acting i.m. fulvestrant formulation in
healthy postmenopausal female volunteers indicated slow absorp-
tion with maximum plasma concentrations (Cmax) being achieved
at 12–24h postinjection. In contrast, following single i.m.
injections of long-acting fulvestrant at doses of up to 250mg in
various trials, the time to Cmax (tmax) varied between 2 and 19 days,
indicating prolonged release of fulvestrant from the injection
site. After Cmax, plasma concentrations of fulvestrant declined
slowly and it was possible to define plasma profiles over at
least 2873 days (i.e. the intended dosing period) in most
subjects after a single dose, and profiles were approximately log-
linear over this time scale (Harrison et al, 2003). Pharmacokinetic
parameters following a single dose of long-acting i.m. fulvestrant
in healthy postmenopausal female volunteers and in postmeno-
pausal women with advanced breast cancer are shown in Table 1.
The pharmacokinetic behaviour of fulvestrant after a single
long-acting 250mg i.m. dose appears to be similar in these two
populations.
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patients given a single 250mg dose of long-acting i.m. fulvestrant
suggest that the plasma concentration–time data fit a two-
compartment model. The different sampling frequency used to
gather data in the i.v. study enables a more complex three-
compartment model to be assigned. The apparent t1/2 observed in
these studies (40 days) was approximately 40 times longer than
that of an i.v. injection of fulvestrant (AstraZeneca, data on file).
Comparisons of fulvestrant plasma profiles obtained following i.v.
or i.m. administration show the marked effects of the i.m.
formulations (short-acting or long-acting) on the release of
fulvestrant into the circulation compared with i.v. administration
(Figure 1). In particular, the difference between the two i.m.
formulations clearly demonstrates the prolonged release charac-
teristics of the long-acting formulation.
An analysis of the single-dose (50, 125, 250mg) pharmacoki-
netics from a trial of long-acting i.m. fulvestrant in postmenopau-
sal women with previously untreated primary breast cancer
showed that Cmax and area under the plasma concentration–time
curve from zero to 28 days (AUC(0–28)) appeared to increase in a
dose-related manner (Robertson et al, 2001). Formal statistical
analysis of covariance indicated that exposure was approximately
proportional to the dose (proportionality coefficient: 0.88; 95%
confidence interval (CI) 0.74–1.03; P¼0.1112).
Multiple-dose i.m. studies using the long-acting
formulation of fulvestrant
Fulvestrant has been licensed in the USA since April 2002. Here,
nursing guidelines have previously suggested that, for adults, i.m.
injections into large muscles such as the gluteus medias should not
usually exceed 4ml (Beyea and Nicoll, 1996). Therefore, when a
US-based Phase III study was initiated, it was decided to use
2 2.5ml i.m. fulvestrant injections, one into each buttock, rather
than a single 5ml i.m. fulvestrant injection (Howell et al, 2002).
However, the 2 2.5ml injections were sufficiently well tolerated
(with a similar incidence of injection-site reactions observed for
placebo and fulvestrant), that most US institutions now prefer to
administer fulvestrant as a single 5ml monthly injection, thereby
reducing the number of injections given to the patient (AstraZe-
neca, data on file). Similar pharmacokinetic properties of the
1 5ml and 2 2.5ml fulvestrant regimens have been demon-
strated in a study of postmenopausal women with advanced breast
cancer. No significant differences in the AUC, plasma concentra-
tion at 28 days (Cmin), and ratio of geometric means of AUC0–28
(1.01; 95% CI 0.68–1.51; P¼0.94) were observed between the two
regimens (Robertson and Harrison, 2003). When i.m. fulvestrant
250mg was given monthly until disease progression, fulvestrant
plasma concentration profiles reached a steady state after 3–6
doses. The predicted steady-state plasma fulvestrant exposures
(AUCss) were very similar for the two dose regimens (1 5ml:
336ngdayml
 1;2  2.5ml: 294ngdayml
 1). Both regimens were
equally effective in maintaining plasma levels for at least 30
months (Robertson and Harrison, 2003). With repeated adminis-
tration, there was no evidence of a change in the pharmacokinetic
behaviour of fulvestrant compared with that observed following
the first injection, and Phase III trial data have since supported this
observation (Robertson et al, 2003). Multiple-dose pharmacoki-
netics were modelled, and showed that blood levels of fulvestrant
were maintained within a narrow range throughout the assessment
period, thus confirming the linearity of fulvestrant pharmacoki-
netics during repeated administration over a prolonged period.
In a small study where 19 postmenopausal patients with
tamoxifen-resistant advanced breast cancer were given fulvestrant
250mg (1 5ml i.m. injection, monthly), the Cmax for fulvestrant
during the first month was 10.5ngml
 1 and was 12.6ngml
 1
during the sixth month. Similarly, the AUC rose from
140.5ngdayml
 1 in the first month to 206.8ngdayml
 1 in the
sixth month, suggesting some drug accumulation (Howell et al,
1996). Two- to three-fold accumulation of fulvestrant with
continued dosing has also been observed in several other studies
using long-acting i.m. fulvestrant (DeFriend et al, 1994; Robertson
and Harrison, 2001). For example, in one of these studies, the
mean trough concentrations of i.m. fulvestrant were found to be
6.1ngml
 1 after 6 months of fulvestrant 250mg treatment
compared with 2.8ngml
 1 after the first month (Robertson and
Harrison, 2001). In summary, the long-acting 250mg i.m.
formulation (administered every 2873 days) is convenient for
the patient, allowing sustained exposure to fulvestrant with plasma
levels maintained over the predicted biological threshold for at
least 28 days.
METABOLISM OF FULVESTRANT
In vitro studies have indicated that fulvestrant is extensively
metabolised. The metabolism of [
14C]-fulvestrant following
i.m. administration was initially investigated in animal studies
(rats and dogs), which showed that fulvestrant was highly
metabolised and mostly excreted in faeces (indicative of biliary
metabolism). Little renal excretion was evident. The metabolite
profiles were similar in rats and dogs, differing only in the relative
proportions of individual components. The major excretory
metabolites in these species were fulvestrant and its 17-ketone
and/or sulphone analogues (rat: 15–20%; dog: 61%) together with
material corresponding to sulphate conjugates (up to 16%). These
results were consistent with earlier in vitro data (AstraZeneca, data
on file).
Table 1 Pharmacokinetic parameters following a single dose of long-
acting i.m. fulvestrant 250mg in healthy female postmenopausal volunteers
(AstraZeneca, data on file) and in postmenopausal women with advanced
breast cancer (Trial 0020, Robertson et al, 2003a)
Healthy
volunteers
Breast cancer
patients
(study 0020)
AUC(0–28) (ngml
 1) gmean (CV, %) 176 (34.5) (n¼10) 148 (45.3) (n¼13)
Cmax (ngml
 1) gmean (CV, %) 11.4 (44.8) (n¼10) 8.20 (63.8) (n¼16)
tmax (h) median 144.0 (n¼10) 167.3 (n¼15)
Cmin (ngml
 1) gmean (CV, %) 2.6 (25.2) (n¼10) 2.62 (33.4) (n¼14)
gmean¼geometric mean; SD¼standard deviation; CV¼coefficient of variation;
AUC(0–28)¼ area under the plasma concentration–time curve from 0 to 28 days;
Cmax¼maximum plasma concentration; tmax¼time to Cmax; Cmin¼minimum plasma
concentration.
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Figure 1 Mean plasma concentrations of fulvestrant following i.v. and
i.m. (short-acting or long-acting) administration.
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14C]-fulvestrant has been
investigated in man. The i.v. trial was an open study in which four
male and four postmenopausal female volunteers each received
10mg [
14C]-fulvestrant, as a 1-h i.v. infusion. Following admin-
istration, distribution of the drug was rapid, with plasma levels
declining soon after the infusion, and, by 2h, postinfusion
geometric mean (gmean) levels of only 15.6 and 12.8ngml
 1 were
detected in male and female volunteers, respectively. At the end of
the 1-h infusion, [
14C]-fulvestrant accounted for approximately
80% of the total plasma radioactivity, declining to about 30% after
2h. This suggests that fulvestrant is quickly metabolised when
administered intravenously.
The i.m. study was also an open trial, including four male and
three postmenopausal female volunteers, each of whom received a
single i.m. 18mg dose of short-acting [
14C]-fulvestrant, in order to
minimise the duration of exposure of the volunteers to the
radioactive label. Following injection, slow absorption resulted in
low levels of [
14C]-fulvestrant being maintained for several hours
(gmean of 14.6ngml
 1 at 8h in males and 13.3ngml
 1 at 24h in
females). At 1h postinjection, [
14C]-fulvestrant accounted for
approximately 90% of the total plasma radioactivity, thereafter
decreasing to about 50% and declining further after 24h. The
majority of fulvestrant and/or its metabolites were associated
with the plasma rather than the cellular components of the
blood (typically 30–70% higher values for plasma compared
with whole blood) in both the i.v. and i.m. studies (Harrison et al,
2003).
As seen in animals, the major route of excretion was via the
faeces (approximately 80 and 90% in the i.v. and i.m. trials,
respectively), with less than 1% being excreted in the urine. In
general, the faecal metabolite profiles of [
14C]-fulvestrant
were similar after i.v. or i.m. delivery, although the proportion
of each type of metabolite differed depending on the route
of administration. Fulvestrant was converted at the 3- and
17-positions of the steroid nucleus to form ketone, sulphate
and glucuronide metabolites, and at the 9-position to form
sulphone metabolites (Harrison et al, 2003) (Figure 2).
These metabolites have been synthesised and tested for pharmaco-
logical activity in vitro. These studies have shown that all the
putative metabolites possess no oestrogenic activity and only the
17-keto compound demonstrated a level of antioestrogenic activity
of the same order of magnitude, but 4.5-fold less than that of
fulvestrant.
POTENTIAL FOR CYP-MEDIATED DRUG
INTERACTIONS
Cytochrome p450 (p450 or CYP) is an enzyme responsible for the
metabolism of a wide variety of drugs (Dresser et al, 2000)
including many anticancer agents (Kivisto et al, 1995, 1998; Crewe
et al, 1997). Therefore, it is important to investigate the potential
for CYP interactions to occur with any new drugs in development.
In in vitro studies, human liver microsomal protein was incubated
with selected CYP substrates in the presence of a range of
concentrations of fulvestrant (up to 2mgml
 1). Although concen-
tration-related inhibition of some of the enzymes (CYP1A2, 2C9
and 3A4) was apparent, these effects were minimal, with less than
20% inhibition occurring at the highest concentration tested
(AstraZeneca, data on file). Fulvestrant did not inhibit the CYP
2C19 and 2D6 isoforms.
The marked inhibition of most fulvestrant metabolic
pathways by ketoconazole provided further evidence for the
involvement of CYP3A4 in the microsomal metabolism of
fulvestrant. Selective inhibitors of CYP 1A2, 2C9, 2C19 and 2D6
had no effect on fulvestrant metabolism. This was confirmed by
the finding that recombinant CYP3A4 readily metabolises
[
14C]-fulvestrant, producing HPLC profiles that were qualitatively
similar to human liver microsomal profiles. Metabolism was
not observed in incubations of [
14C]-fulvestrant with expressed
CYP 1A2, 2C9, 2C19, 2D6, or flavin mono-oxygenase (FMO-3).
Although fulvestrant readily undergoes CYP3A4-mediated meta-
bolism when incubated with human liver microsomes, in vitro
studies using human hepatocytes indicated that sulphate
conjugation was a more predominant pathway. Therefore,
CYP3A4 does not seem likely to have a major role in the
overall clearance of the drug, and fulvestrant would not be
expected to cause clinically significant drug interactions
through inhibition of P450-mediated metabolism of co-adminis-
tered agents.
Two randomised crossover studies have been conducted in
healthy volunteers, to confirm that fulvestrant is not subject to
CYP3A4 interactions that may potentially affect the safety or
efficacy of the drug. These studies demonstrated that the
pharmacokinetics of fulvestrant are not significantly affected
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Figure 2 Structure of fulvestrant and points of metabolism.
Table 2 Lack of potential for fulvestrant to be involved in significant CYP3A4-mediated drug interactions. Data are geometric least squares mean
(glsmean) area under the concentration-time curve from 0 to time t (AUC[0 t]) for fulvestrant (rifampicin and ketoconazole studies) and AUC for
midazolam (midazolam study)
Fulvestrant 10mg i.v.+rifampicin
600mg (n¼6)
Fulvestrant 10mg
i.v. alone (n¼6) Treatment effect
a
Lower one-sided
95% CI Upper 95% CI
208nghml
 1 211nghml
 1 0.99
b 0.65
b 1.49
Fulvestrant 8mg i.v.+ketoconazole
400mg (n¼18)
Fulvestrant 8mg i.v. alone (n¼18) Treatment effect
a Lower 90% CI Upper 90% CI
130.6nghml
 1 143.3nghml
 1 0.91 0.83 1.00
Midazolam 7.5mg+fulvestrant
36mg i.m. (n¼7)
Midazolam 7.5mg alone (n¼7) Treatment effect
a Lower 90% CI Upper 90% CI
135nghml
 1 123nghml
 1 1.11 0.83 1.47
aRatio of glsmeans;
bbased on data from five volunteers.
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inhibit (e.g. ketoconazole) CYP3A4 activity. In an additional
randomised crossover study, fulvestrant did not significantly
affect the pharmacokinetics of an agent (midazolam) that
is a model substrate of CYP3A4 (Table 2) (Laight et al, 2003).
These data reinforce the preclinical data and suggest that
fulvestrant is unlikely to be the subject or cause of clinically
significant drug interactions and no adjustments to the
250mg i.m. dose are recommended when it is used in combina-
tion with agents that affect CYP3A4 activity. Further studies
have shown that dosage adjustments are not required in patients
with renal impairment or mild hepatic impairment (AstraZeneca,
data on file).
CONCLUSIONS
Fulvestrant is an ER antagonist that has a novel pharmacological
profile and no agonist effects. Pharmacokinetic data have shown
that i.m. injection of fulvestrant is the most effective mode of
administration, with a single 250mg i.m. injection of the long-
acting fulvestrant formulation maintaining plasma concentrations
within a 2–3-fold range above those predicted to be necessary for
pharmacological activity over the dosing interval (2873 days).
Fulvestrant is highly metabolised and is mainly excreted in the
faeces, and pharmacokinetic studies have also suggested that
fulvestrant is unlikely to be the subject, or cause, of significant
CYP3A4-mediated drug interactions.
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